Explore

Trendline Trendline
Merck's TroFuse-005 Trial Achieves Key Endpoints in Advanced Endometrial Cancer Treatment

Merck's TroFuse-005 Trial Achieves Key Endpoints in Advanced Endometrial Cancer Treatment

Merck's TroFuse-005 Trial Achieves Key Endpoints in Advanced Endometrial Cancer Treatment
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments
Trendline Trendline
Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment
Trendline Trendline
Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial

Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial

Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial
Trendline Trendline
Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial

Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial

Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial
Trendline Trendline
ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage